2006. Newborn screening: toward a uniform screening panel and system. Genet Med 8 Suppl 1:1S-252S.
Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, Mackey J, Kishnani P, Smith W, McVie-Wylie A and others. 2001. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 3(2):132-8.
Araoz C, Sun CN, Shenefelt R, White HJ. 1974. Glycogenosis type II (Pompe's disease):
ultrastructure of peripheral nerves. Neurology 24(8):739-42.
Barkovich AJ, Kjos BO. 1988. Normal postnatal development of the corpus callosum as demonstrated by MR imaging. AJNR Am J Neuroradiol 9(3):487-91.
Barkovich AJ, Kjos BO, Jackson DE, Jr., Norman D. 1988. Normal maturation of the neonatal and infant brain: MR imaging at 1.5 T. Radiology 166(1 Pt 1):173-80.
Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263-5.
Bashan N, Potashnik R, Barash V, Gutman A, Moses SW. 1988. Glycogen storage disease type II in Israel. Isr J Med Sci 24(4-5):224-7.
Bembi B, Ciana G, Martini C, Benettoni A, Gombacci A, Deganuto M, Pittis MG. 2003.
Efficacy of multidisciplinary approach in the treatment of two cases of nonclassical infantile glycogenosis type II. J Inherit Metab Dis 26(7):675-81.
Bijvoet AG, Van Hirtum H, Kroos MA, Van de Kamp EH, Schoneveld O, Visser P, Brakenhoff JP, Weggeman M, van Corven EJ, Van der Ploeg AT and others.
1999. Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet 8(12):2145-53.
Boerkoel CF, Exelbert R, Nicastri C, Nichols RC, Miller FW, Plotz PH, Raben N. 1995.
Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. Am J Hum Genet 56(4):887-97.
Case LE, Koeberl DD, Young SP, Bali D, DeArmey SM, Mackey J, Kishnani PS. 2008.
Improvement with ongoing Enzyme Replacement Therapy in advanced late-onset Pompe disease: a case study. Mol Genet Metab 95(4):233-5.
47
Chamoles NA, Niizawa G, Blanco M, Gaggioli D, Casentini C. 2004. Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. Clin Chim Acta 347(1-2):97-102.
de Barsy T, Jacquemin P, Van Hoof F, Hers HG. 1973. Enzyme replacement in Pompe disease: an attempt with purified human acid alpha-glucosidase. Birth Defects Orig Artic Ser 9(2):184-90.
Guthrie R. 1992. The origin of newborn screening. Screening 1:5-15.
Hermans MM, de Graaff E, Kroos MA, Wisselaar HA, Willemsen R, Oostra BA, Reuser AJ. 1993. The conservative substitution Asp-645-->Glu in lysosomal alpha-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II. Biochem J 289 ( Pt 3):687-93.
Hermans MM, Kroos MA, van Beeumen J, Oostra BA, Reuser AJ. 1991. Human lysosomal alpha-glucosidase. Characterization of the catalytic site. J Biol Chem 266(21):13507-12.
Hermans MM, van Leenen D, Kroos MA, Beesley CE, Van Der Ploeg AT, Sakuraba H, Wevers R, Kleijer W, Michelakakis H, Kirk EP and others. 2004. Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat 23(1):47-56.
Hesselink RP, Wagenmakers AJ, Drost MR, Van der Vusse GJ. 2003. Lysosomal dysfunction in muscle with special reference to glycogen storage disease type II.
Biochim Biophys Acta 1637(2):164-70.
Hirschhorn R. 2001. Glycogen storage disease type II:acid-glucosidase (acid maltase) deficiency. New York McGraw-Hill.
Hirschhorn RRA, Reuser AJ. 2001. Glycogen storage disease type II:acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited diseases.
New York McGraw-Hill. p 3389-3420.
Huie ML, Chen AS, Brooks SS, Grix A, Hirschhorn R. 1994. A de novo 13 nt deletion, a newly identified C647W missense mutation and a deletion of exon 18 in infantile onset glycogen storage disease type II (GSDII). Hum Mol Genet
3(7):1081-7.
Huie ML, Menaker M, McAlpine PJ, Hirschhorn R. 1996. Identification of an E689K substitution as the molecular basis of the human acid alpha-glucosidase type 4 allozyme (GAA*4). Ann Hum Genet 60(Pt 5):365-8.
Huie ML, Tsujino S, Sklower Brooks S, Engel A, Elias E, Bonthron DT, Bessley C, Shanske S, DiMauro S, Goto YI and others. 1998. Glycogen storage disease type II: identification of four novel missense mutations (D645N, G648S, R672W, R672Q) and two insertions/deletions in the acid alpha-glucosidase locus of patients of differing phenotype. Biochem Biophys Res Commun 244(3):921-7.
Kallwass H, Carr C, Gerrein J, Titlow M, Pomponio R, Bali D, Dai J, Kishnani P, Skrinar A, Corzo D and others. 2007. Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots.
Mol Genet Metab 90(4):449-52.
Kemper AR, Hwu WL, Lloyd-Puryear M, Kishnani PS. 2007. Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations. Pediatrics 120(5):e1327-34.
Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M and others. 2007. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.
Neurology 68(2):99-109.
Kishnani PS, Howell RR. 2004. Pompe disease in infants and children. J Pediatr 144(5 Suppl):S35-43.
Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. 2006a. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148(5):671-676.
Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J, Herman GE, Amalfitano A, Thurberg BL, Richards S and others. 2006b. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 149(1):89-97.
Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, Crowley JF, Downs S, Howell RR, Kravitz RM and others. 2006c. Pompe disease diagnosis and
49
management guideline. Genet Med 8(5):267-88.
Klinge L, Straub V, Neudorf U, Schaper J, Bosbach T, Gorlinger K, Wallot M, Richards S, Voit T. 2005a. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 15(1):24-31.
Klinge L, Straub V, Neudorf U, Voit T. 2005b. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
Neuropediatrics 36(1):6-11.
Ko TM, Hwu WL, Lin YW, Tseng LH, Hwa HL, Wang TR, Chuang SM. 1999.
Molecular genetic study of Pompe disease in Chinese patients in Taiwan. Hum Mutat 13(5):380-4.
Kroos MA, Kirschner J, Gellerich FN, Hermans MM, Van Der Ploeg AT, Reuser AJ, Korinthenberg R. 2004. A case of childhood Pompe disease demonstrating phenotypic variability of p.Asp645Asn. Neuromuscul Disord 14(6):371-4.
Kroos MA, Mullaart RA, Van Vliet L, Pomponio RJ, Amartino H, Kolodny EH, Pastores GM, Wevers RA, Van der Ploeg AT, Halley DJ and others. 2008.
p.[G576S; E689K]: pathogenic combination or polymorphism in Pompe disease ? Eur J Hum Genet.
Kroos MA, Pomponio RJ, Hagemans ML, Keulemans JL, Phipps M, DeRiso M, Palmer RE, Ausems MG, Van der Beek NA, Van Diggelen OP and others. 2007. Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
Neurology 68(2):110-5.
Kroos MA, Van der Kraan M, Van Diggelen OP, Kleijer WJ, Reuser AJ, Van den Boogaard MJ, Ausems MG, Ploos van Amstel HK, Poenaru L, Nicolino M and others. 1995. Glycogen storage disease type II: frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients. J Med Genet 32(10):836-7.
Kwon C, Farrell PM. 2000. The magnitude and challenge of false-positive newborn screening test results. Arch Pediatr Adolesc Med 154(7):714-8.
Li Y, Scott CR, Chamoles NA, Ghavami A, Pinto BM, Turecek F, Gelb MH. 2004.
Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 50(10):1785-96.
Lin CY, Hwang B, Hsiao KJ, Jin YR. 1987. Pompe's disease in Chinese and prenatal diagnosis by determination of alpha-glucosidase activity. J Inherit Metab Dis 10(1):11-7.
Lin CY, Shieh JJ. 1996. Molecular study on the infantile form of Pompe disease in Chinese in Taiwan. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 37(2):115-21.
Martiniuk F, Bodkin M, Tzall S, Hirschhorn R. 1990. Identification of the base-pair substitution responsible for a human acid alpha glucosidase allele with lower
"affinity" for glycogen (GAA 2) and transient gene expression in deficient cells.
Am J Hum Genet 47(3):440-5.
Martiniuk F, Chen A, Mack A, Arvanitopoulos E, Chen Y, Rom WN, Codd WJ, Hanna B, Alcabes P, Raben N and others. 1998. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet 79(1):69-72.
Merk T, Wibmer T, Schumann C, Kruger S. 2009. Glycogen storage disease type II (Pompe disease)--influence of enzyme replacement therapy in adults. Eur J Neurol 16(2):274-7.
Montalvo AL, Bembi B, Donnarumma M, Filocamo M, Parenti G, Rossi M, Merlini L, Buratti E, De Filippi P, Dardis A and others. 2006. Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat 27(10):999-1006.
Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR, Arnold GL, Pivnick EK, Ottinger CJ, Robinson PH and others. 2009. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 11(3):210-9.
Okumiya T, Keulemans JL, Kroos MA, Van der Beek NM, Boer MA, Takeuchi H, Van Diggelen OP, Reuser AJ. 2006. A new diagnostic assay for glycogen storage disease type II in mixed leukocytes. Mol Genet Metab 88(1):22-8.
Olgemoller B, Roscher AA, Liebl B, Fingerhut R. 2003. Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. J Clin Endocrinol Metab 88(12):5790-4.
51
Ponce E, Witte DP, Hirschhorn R, Huie ML, Grabowski GA. 1999. Murine acid alpha-glucosidase: cell-specific mRNA differential expression during development and maturation. Am J Pathol 154(4):1089-96.
Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP. 1999. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105(1-2):151-6.
Raben N, Jatkar T, Lee A, Lu N, Dwivedi S, Nagaraju K, Plotz PH. 2002a. Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. Mol Ther 6(5):601-8.
Raben N, Plotz P, Byrne BJ. 2002b. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2(2):145-66.
Shieh JJ, Lin CY. 1998. Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect. Hum Mutat 11(4):306-12.
Shin YS, Endres W, Unterreithmeier J, Rieth M, Schaub J. 1985. Diagnosis of Pompe's disease using leukocyte preparations. Kinetic and immunological studies of 1,4-alpha-glucosidase in human fetal and adult tissues and cultured cells. Clin Chim Acta 148(1):9-19.
Slonim AE, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F. 2000. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr 137(2):283-5.
Sontag MK, Hammond KB, Zielenski J, Wagener JS, Accurso FJ. 2005. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. J Pediatr 147(3 Suppl):S83-8.
Sun B, Bird A, Young SP, Kishnani PS, Chen YT, Koeberl DD. 2007. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet 81(5):1042-9.
Suzuki Y, Tsuji A, Omura K, Nakamura G, Awa S, Kroos M, Reuser AJ. 1988. Km mutant of acid alpha-glucosidase in a case of cardiomyopathy without signs of skeletal muscle involvement. Clin Genet 33(5):376-85.
Swallow DM, Kroos M, Van der Ploeg AT, Griffiths B, Islam I, Marenah CB, Reuser AJ. 1989. An investigation of the properties and possible clinical significance of
the lysosomal alpha-glucosidase GAA*2 allele. Ann Hum Genet 53(Pt 2):177-84.
Tajima Y, Matsuzawa F, Aikawa S, Okumiya T, Yoshimizu M, Tsukimura T, Ikekita M, Tsujino S, Tsuji A, Edmunds T and others. 2007. Structural and biochemical studies on Pompe disease and a "pseudodeficiency of acid alpha-glucosidase". J Hum Genet 52(11):898-906.
Taniguchi N, Kato E, Yoshida H, Iwaki S, Ohki T, Koizumi S. 1978. alpha-glucosidase activity in human leucocytes: choice of lymphocytes for the diagnosis of Pompe's disease and the carrier state. Clin Chim Acta 89(2):293-9.
Thurberg BL, Lynch Maloney C, Vaccaro C, Afonso K, Tsai AC, Bossen E, Kishnani PS, O'Callaghan M. 2006. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease. Lab Invest 86(12):1208-20.
Tsujino S, Huie M, Kanazawa N, Sugie H, Goto Y, Kawai M, Nonaka I, Hirschhorn R, Sakuragawa N. 2000. Frequent mutations in Japanese patients with acid maltase deficiency. Neuromuscul Disord 10(8):599-603.
van Capelle CI, Winkel LP, Hagemans ML, Shapira SK, Arts WF, van Doorn PA, Hop WC, Reuser AJ, van der Ploeg AT. 2008. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease.
Neuromuscul Disord 18(6):447-52.
van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, Bakker HD, Loonen MC, de Klerk JB, Reuser AJ and others. 2003. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112(2):332-40.
Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, Vulto AG, Cromme-Dijkhuis A, Weisglas-Kuperus N, Hop W and others. 2004.
Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113(5):e448-57.
van der Beek NA, Hagemans ML, van der Ploeg AT, Reuser AJ, van Doorn PA. 2006.
Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy. Acta Neurol Belg 106(2):82-6.
Wan L, Lee CC, Hsu CM, Hwu WL, Yang CC, Tsai CH, Tsai FJ. 2008. Identification
53
of eight novel mutations of the acid alpha-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II. J Neurol 255(6):831-8.
Winchester B, Bali D, Bodamer OA, Caillaud C, Christensen E, Cooper A, Cupler E, Deschauer M, Fumic K, Jackson M and others. 2008. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab 93(3):275-81.
Winkel LP, Van den Hout JM, Kamphoven JH, Disseldorp JA, Remmerswaal M, Arts WF, Loonen MC, Vulto AG, Van Doorn PA, De Jong G and others. 2004.
Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 55(4):495-502.
Wisselaar HA, Kroos MA, Hermans MM, van Beeumen J, Reuser AJ. 1993. Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem 268(3):2223-31.
Yang HW, Kikuchi T, Hagiwara Y, Mizutani M, Chen YT, Van Hove JL. 1998.
Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts. Pediatr Res 43(3):374-80.
Yue P, Li Z, Moult J. 2005. Loss of protein structure stability as a major causative factor in monogenic disease. J Mol Biol 353(2):459-73.
Yue P, Moult J. 2006. Identification and analysis of deleterious human SNPs. J Mol Biol 356(5):1263-74.
Zhang H, Kallwass H, Young SP, Carr C, Dai J, Kishnani PS, Millington DS, Keutzer J, Chen YT, Bali D. 2006. Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease. Genet Med 8(5):302-6.